KU Leuven registers interventional Aveir leadless pacemaker study; not yet recruiting
A Belgium-Luxembourg network led by KU Leuven has registered a single-arm interventional study of Abbott's Aveir leadless pacemaker systems, with Abbott named as a collaborator.
The week's only new filing for this program is a single trial registration.
- The study is listed as interventional, not yet recruiting, and largely follows standard-of-care protocol, adding a 24-hour Holter monitoring assessment in a selected group of patients after one year and a CT scan at UZ Leuven to confirm pacemaker position.1 Universitaire Ziekenhuizen KU Leuven is the lead sponsor, with Abbott Medical Devices listed as a collaborator.
Fact check notes
- Sentence removed
"Belgo-Luxembourg Collaborative Research Network on AVEIR Leadless Pacemakers" (NCT07879716, acronym BELLA) is a single-arm, multicenter clinical study evaluating the long-term effectiveness and safety profile of the CE-marked and commercially available Aveir leadless pacemaker systems manufactured by Abbott.
copied source wording - Sentence removed
Estimated enrollment is 190 participants, with an estimated start date of November 1, 2026.
a figure with no citation
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Where the check questioned a sentence, its note is shown above. Not investment advice.